Altimmune (ALT) Profit After Tax (2010 - 2026)

Altimmune (ALT) has 17 years of Profit After Tax data on file, last reported at -$22.9 million in Q1 2026.

• On a quarterly basis, Profit After Tax fell 16.6% year-over-year to -$22.9 million in Q1 2026; TTM through Mar 2026 was -$91.4 million, a 1.26% decrease from a year earlier, with the FY2025 full-year figure at -$88.1 million, up 7.3% from the prior year.
• Profit After Tax for Q1 2026 stood at -$22.9 million, up from -$27.4 million in the prior quarter.
• Over the last five years, Profit After Tax for ALT reached as high as -$16.1 million in Q2 2023 and fell as low as -$31.6 million in Q4 2023.
• Historically, Profit After Tax has averaged -$22.3 million across 5 years, with a median of -$22.1 million in 2025.
• Across the five-year window, Profit After Tax climbed 29.4% in 2022 and plunged 53.42% in 2024, its largest moves.
• Year by year, Profit After Tax stood at -$21.7 million in 2022, then plunged by 46.08% to -$31.6 million in 2023, then increased by 26.84% to -$23.1 million in 2024, then retreated by 18.18% to -$27.4 million in 2025, then gained by 16.44% to -$22.9 million in 2026.
• Per Business Quant data, the three most recent Profit After Tax figures were -$22.9 million in Q1 2026, -$27.4 million in Q4 2025, and -$19.0 million in Q3 2025.